![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly’s Arthritis Drug Reduces COVID-19 Mortality, Study Finds
Eli Lilly’s Arthritis Drug Reduces COVID-19 Mortality, Study Finds
Eli Lilly’s rheumatoid arthritis treatment Olumiant (baricitinib) inhibited the coronavirus and reduced mortality in COVID-19 patients by 71 percent, according to researchers from the Sweden’s Karolinska Institutet.
Published in Science Advances, the study enrolled 83 hospitalized elderly COVID-19 patients in Italy and Spain who were treated with baricitinib and standard of care vs. standard of care alone.
In October, the company released results from a phase 3 study that showed baricitinib combined with Gilead Sciences’ antiviral remdesivir reduced COVID-19 patient recovery time by 12.5 percent, or from eight to seven days, vs. remdesivir alone.
Upcoming Events
-
21Oct